Fischer’s financial slump continues in Q2
Fischer Imaging of Denver continues to drift in financial doldrums. Despite increases in its second-quarter 1999 (end-July) revenues—the company posted $16.7 million for the quarter, up 9% from $15.2 million for the same period the previous
Fischer Imaging of Denver continues to drift in financial doldrums. Despite increases in its second-quarter 1999 (end-July) revenuesthe company posted $16.7 million for the quarter, up 9% from $15.2 million for the same period the previous yearFischer sustained a net loss for the quarter of approximately $2 million, including a restructuring charge. Without the charge, the companys net loss was $1.2 million, compared to $984,000 in 1998.
Fischers moderate sales growth for the period was due to increases in mammography and service revenues offset by reductions in OEM shipments, according to vice president of finance Bill Fee. Its operating results for the quarter were disappointing, Fee said: Manufacturing variances were high, while production hours were lower than the year before. The $700,000 restructuring charge occurred when Fischer discontinued a product line manufactured at one of its facilities that the company was unable to relocate to Denver. In an effort to cut operating costs, the company reduced its inventory by more than $3 million, and last month cut its staff by 5%.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
